Research Reports

Key takeaways

Board elected Kimberly J. Popovits as non-employee Class II director effective April 1, 2026, to serve until 2028 annual meeting.

Edward T. Mathers resigned from Board effective April 1, 2026, with no disagreements on company operations, policies or practices.

Popovits compensated per non-employee director policy filed as Exhibit 10.6 to 2025 10-K.

Popovits and Company to enter standard indemnification agreement filed as Exhibit 10.1 to 2025 10-K.

Press release issued April 3, 2026, announcing board changes (Exhibit 99.1).

Full analysis

Rhythm Pharmaceuticals refreshed its Board with the addition of Kimberly J. Popovits, an experienced life sciences leader with over 40 years in biotechnology, diagnostics, and commercialization, including prior CEO role at Genomic Health and leadership at Genentech. Her expertise in commercialization, reimbursement, and governance is highlighted as valuable for the company's mission and growth. Edward T. Mathers' departure after service since 2013 was amicable, with acknowledgment of his strategic contributions. Popovits will follow standard non-employee director compensation and indemnification terms previously disclosed in the 2025 10-K. This change signals continuity in board composition while adding commercial-stage biopharma depth.

RYTM · Rhythm Pharmaceuticals, Inc.

Summary

Key takeaways

Full analysis